// App-Quantinova.ai

CTIM-06 : EVALUATING THE ASSOCIATION BETWEEN PERIPHERAL BLOOD IMMUNOLOGIC RESPONSE AND THERAPEUTIC RESPONSE TO IMMUNE CHECKPOINT INHIBITION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA AND GLIOSARCOMA

Researchers

Presenter

  • Matthew Watowich

Principal Investigators

  • Nasser Yaghi

  • Nicole Briceno

  • Susie Ahn

  • Kathleen Wall

  • KAREN EVANS

  • Lily Polskin

  • Edina Komlodi-Pasztor

  • Solmaz Sahebjam

  • Masashi Watanabe

  • Mark Gilbert

Medical Centers

  • Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

  • National Institutes of Health, National Cancer Institute (NCI), Center for Cancer Research (CCR), Neuro-Oncology Branch (NOB), Washington, DC, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

  • Gliosarcoma

  • Brain cancer

Biomarkers

  • Peripheral blood mononuclear cell

Drug/Treatment

  • Ipilimumab

  • Interferon

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved